How much funding has Helixon raised?

Helixon has raised $74.7M in total funding, most recently a Series A round.

Who are Helixon's investors?

Helixon's investors include Gaorong Capital, 5Y Capital, Hillhouse Capital, Xiang He Capital.

Where is Helixon headquartered?

Helixon is headquartered in Beijing, China.

What industry is Helixon in?

Helixon operates in Artificial Intelligence, Biotech.

Helixon

AI-powered drug discovery at the frontier of science and computation.

Beijing, China · Founded 2023 · $74.7M raised

Artificial Intelligence

Biotech

Headquarters: Beijing
Employees: 51–200
Founded: 2023
Business Model: B2B

Website: helixon.com.cn
Total Funding: $74.7M
Last Round: $74.7M Series AJun 2022
Rounds: 1

About

Helixon (华深智药) is a global AI-powered biotech company specializing in drug discovery, with headquarters in Beijing and operations in Shanghai and Suzhou, China. Founded in 2023, Helixon has assembled an interdisciplinary team with expertise in machine learning, structural biology, and medicinal chemistry to build a next-generation AI scientific computing platform combined with proprietary high-throughput biological experimentation technology. The company operates through a US-affiliated entity called Earendil Labs, which entered a landmark partnership with Sanofi valued at over $1.8 billion for immune disease drugs HXN-1002 and related compounds. Helixon's model leverages AI to design large molecules, rapidly test them in China, and license out validated drug candidates to global pharmaceutical partners. The company is backed by multiple Chinese venture capital firms and is recognized as a leading player in China's AI drug discovery ecosystem, alongside Insilico Medicine and XtalPi.

Summary

Helixon is an Artificial Intelligence company based in Beijing, China, founded in 2023. It has raised $74.7M in total across 1 round, most recently a $74.7M Series A round in Jun 2022. Investors include Gaorong Capital, 5Y Capital and Hillhouse Capital.